TTE
TTE is an intervention with 6 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 1 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
0
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 1Trial Status & Enrollment
100.0%
1 of 1 finished
0.0%
0 ended early
2
trials recruiting
6
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
TTE Improves Clinical Management of Stable Chest Pain
Speckle Tracking and Inhaled Nitric Oxide in Acute Respiratory Distress Syndrome
A Study to Evaluate the Feasibility of Screening Relatives of Patients Affected by Non-Syndromic Thoracic Aortic Diseases
Real-time Continuous Cardiac Output Measurements
Clinical Trials (6)
Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
TTE Improves Clinical Management of Stable Chest Pain
Speckle Tracking and Inhaled Nitric Oxide in Acute Respiratory Distress Syndrome
A Study to Evaluate the Feasibility of Screening Relatives of Patients Affected by Non-Syndromic Thoracic Aortic Diseases
Real-time Continuous Cardiac Output Measurements
Acute CorPulmonale and ARDS Circulation Protection China Study China (ACPC)
All 6 trials loaded
Drug Details
- Intervention Type
- DIAGNOSTIC TEST
- Total Trials
- 6